MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

By R. Lalla, J. Bowen, A. Barasch, Linda S. Elting, J. Epstein, Dorothy M. K. Keefe, Deborah B. McGuire, Cesar Migliorati, O. Nicolatou‐Galitis, Douglas E. Peterson and 3 more. Cancer, 2014

1,463 citations recorded by the source corpus.

Mucositis is a highly significant, and sometimes dose‐limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis.

Subfields: Oncology, Otorhinolaryngology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3f0ee8e46218a334fabcd1edcec5b09038dad1a1

Citations in the corpus

• Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis (2017, neutral): “However, mixing several active ingredients results in dilution of each agent and potential incompatibility of products that reduce their overall efficacy, and furthermore, there is limited clinical evidence that magic mouthwash is efficacious [11].”